Adaptive Prostate Cancer Therapy Model
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostate cancer treatments, such as continuous androgen deprivation therapy, fail to consider evolutionary dynamics, leading to accelerated emergence of resistant populations and reduced efficacy, as they do not account for the competition and adaptation between treatment-sensitive and resistant cells.
Innovation Solution
A personalized treatment approach using a prostate cancer dynamic model to adjust intermittent androgen deprivation therapy based on patient-specific PSA levels, pausing and resuming treatment, and adjusting the dosage and rate of drugs like docetaxel or abiraterone acetate, to prolong time to progression and survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous maximum tolerable dose (MTD) androgen deprivation therapy is used, then initial tumor control is achieved, but resistant cell populations emerge and accelerate treatment failure
Solution Approach 1:
The patent implements intermittent androgen deprivation therapy (IADT) by periodically switching treatment on and off based on PSA level thresholds. Treatment is activated when PSA exceeds a threshold and deactivated when it falls below a threshold, creating periodic treatment cycles that prevent resistant population emergence while maintaining tumor control over extended periods
Solution Approach 2:
The patent dynamically adjusts treatment status based on real-time PSA measurements and patient-specific model parameters. The system continuously monitors PSA levels and adapts treatment intensity and timing to individual patient response characteristics, optimizing the balance between tumor control and delaying resistance
2Duration of action of stationary object
If intermittent androgen deprivation therapy is used to reduce toxicity and delay progression, then treatment duration is extended, but efficacy is reduced due to elimination of treatment-sensitive cells
Solution Approach 1:
The patent employs feedback control by continuously measuring PSA levels and using them to adjust treatment decisions. Patient-specific responder parameters are calculated from PSA dynamics, and these feedback signals determine when to activate or deactivate treatment, ensuring that treatment intensity matches actual tumor burden and response
Solution Approach 2:
The patent performs preliminary calculation of patient-specific responder parameters from early PSA response data before full intermittent therapy begins. This preliminary characterization of patient response dynamics allows optimization of treatment thresholds and timing to maintain efficacy while extending progression-free survival
3Ease of operation
If fixed PSA threshold protocols are used for IADT, then treatment simplicity is maintained, but individual patient response dynamics are not optimized
Solution Approach 1:
The patent applies local quality by calculating patient-specific responder parameters tailored to each individual's PSA dynamics. Instead of universal thresholds, each patient receives customized treatment thresholds and timing based on their unique response characteristics, optimizing treatment for their specific tumor biology while maintaining protocol structure
Data Source
AI summary
Disclosed are methods for personalized treatment of tumor lesions in subject following primary tumor treatment. Disclosed are methods related to using patient specific prostate cancer dynamic model to adjust a patient's intermittent androgen deprivation therapy to determine when to pause IADT, when to resume IADT, the amount of treatment, and the rate of treatment and thereby increasing the time to progression of the tumor and thus prolonging post cancer treatment survival.